NEXGEL To Report First Quarter 2025 Financial Results On May 13Th

2025-05-09 09:05:38

(MENAFN- GlobeNewsWire - Nasdaq) Management will host a conference call at 4:30 P.M. ET on the same day

LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the“Company”) (NASDAQ:“NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p.m. ET on the same day.

First Quarter 2025 Financial Results Conference Call
Date: May 13, 2025
Time: 4:30 P.M. ET
Live Call: 1-800-343-4849 (U.S. Toll Free) or 1-203-518-9848 (International)
Webcast: Events and Presentations

For interested individuals unable to join the conference call, a replay will be available through May 27, 2025, by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11159118. An archived version of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal^®, Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
...

MENAFN09052025004107003653ID1109528784

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.